{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "30300411",
  "DateCompleted": {
    "Year": "2019",
    "Month": "03",
    "Day": "20"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "03",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "10",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e0205316",
      "10.1371/journal.pone.0205316"
    ],
    "Journal": {
      "ISSN": "1932-6203",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "10",
        "PubDate": {
          "Year": "2018"
        }
      },
      "Title": "PloS one",
      "ISOAbbreviation": "PLoS One"
    },
    "ArticleTitle": "Antimicrobial treatment practices among Ugandan children with suspicion of central nervous system infection.",
    "Pagination": {
      "StartPage": "e0205316",
      "MedlinePgn": "e0205316"
    },
    "Abstract": {
      "AbstractText": [
        "Acute central nervous system (CNS) infections in children in sub-Saharan Africa are often fatal. Potential contributors include late presentation, limited diagnostic capacity and inadequate treatment. A more nuanced understanding of treatment practices with a goal of optimizing such practices is critical to prevent avoidable case fatality. We describe empiric antimicrobial treatment, antibiotic resistance and treatment adequacy in a prospective cohort of 459 children aged two months to 12 years hospitalised for suspected acute CNS infections in Mbarara, Uganda, from 2009 to 2012. Among these 459 children, 155 had a laboratory-confirmed diagnosis of malaria (case-fatality rate [CFR] 14%), 58 had bacterial infections (CFR 24%) and 6 children had mixed malaria and bacterial infections (CFR 17%). Overall case fatality was 18.1% (n = 83). Of 219 children with laboratory-confirmed malaria and/or bacterial infections, 182 (83.1%) received an adequate antimalarial and/or antibiotic on the day of admission and 211 (96.3%) within 48 hours of admission. The proportion of those receiving adequate treatment was similar among survivors and non-survivors. All bacterial isolates were sensitive to ceftriaxone except one Escherichia coli isolate with extended-spectrum beta-lactamase (ESBL). The observed high mortality was not a result of inadequate initial antimicrobial treatment at the hospital. The epidemiology of CNS infection in this setting justifies empirical use of a third-generation cephalosporin, however antibiotic resistance should be monitored closely."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre Mbarara Research Centre, Mbarara, Uganda."
          },
          {
            "Identifier": [],
            "Affiliation": "Mbarara University of Science and Technology, Mbarara, Uganda."
          }
        ],
        "LastName": "Kemigisha",
        "ForeName": "Elizabeth",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre Mbarara Research Centre, Mbarara, Uganda."
          }
        ],
        "LastName": "Nanjebe",
        "ForeName": "Deborah",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre Mbarara Research Centre, Mbarara, Uganda."
          },
          {
            "Identifier": [],
            "Affiliation": "Mbarara University of Science and Technology, Mbarara, Uganda."
          }
        ],
        "LastName": "Boum",
        "ForeName": "Yap",
        "Initials": "Y",
        "Suffix": "2nd"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre, Paris, France."
          }
        ],
        "LastName": "Langendorf",
        "ForeName": "C\u00e9line",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Microbiology Laboratory, Cr\u00e9teil Hospital, France."
          }
        ],
        "LastName": "Aberrane",
        "ForeName": "Said",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre Mbarara Research Centre, Mbarara, Uganda."
          }
        ],
        "LastName": "Nyehangane",
        "ForeName": "Dan",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre, Paris, France."
          }
        ],
        "LastName": "Nackers",
        "ForeName": "Fabienne",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de recherche et de d\u00e9veloppement Policlinique M\u00e9dicale Universitaire, Lausanne, Switzerland."
          }
        ],
        "LastName": "Mueller",
        "ForeName": "Yolanda",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "EPV Emergence des Pathologies, UMR D 190, Marseille, France."
          }
        ],
        "LastName": "Charrel",
        "ForeName": "R\u00e9mi",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States of America."
          }
        ],
        "LastName": "Murphy",
        "ForeName": "Richard A",
        "Initials": "RA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre, Paris, France."
          }
        ],
        "LastName": "Page",
        "ForeName": "Anne-Laure",
        "Initials": "AL"
      },
      {
        "Identifier": [
          "0000-0002-6738-477X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Epicentre Mbarara Research Centre, Mbarara, Uganda."
          },
          {
            "Identifier": [],
            "Affiliation": "Mbarara University of Science and Technology, Mbarara, Uganda."
          }
        ],
        "LastName": "Mwanga-Amumpaire",
        "ForeName": "Juliet",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "PLoS One",
    "NlmUniqueID": "101285081",
    "ISSNLinking": "1932-6203"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "75J73V1629",
      "NameOfSubstance": "Ceftriaxone"
    },
    {
      "RegistryNumber": "EC 3.5.2.6",
      "NameOfSubstance": "beta-Lactamases"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Ceftriaxone"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Central Nervous System Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child, Preschool"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Coinfection"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Drug Resistance, Bacterial"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Escherichia coli"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Escherichia coli Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Infant"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Malaria"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Uganda"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "beta-Lactamases"
    }
  ],
  "CoiStatement": "The authors have declared that no competing interests exist."
}